Success Metrics

Clinical Success Rate
100.0%

Based on 7 completed trials

Completion Rate
100%(7/7)
Active Trials
0(0%)
Results Posted
100%(7 trials)

Phase Distribution

Ph phase_3
3
43%
Ph phase_2
4
57%

Phase Distribution

0

Early Stage

4

Mid Stage

3

Late Stage

Phase Distribution7 total trials
Phase 2Efficacy & side effects
4(57.1%)
Phase 3Large-scale testing
3(42.9%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

100.0%

7 of 7 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

7

all time

Status Distribution
Completed(7)

Detailed Status

Completed7

Development Timeline

Analytics

Development Status

Total Trials
7
Active
0
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Phase 24 (57.1%)
Phase 33 (42.9%)

Trials by Status

completed7100%

Recent Activity

0 active trials
Showing 5 of 7
completedphase_2

Evaluation of SAR440340 and as Combination Therapy With Dupilumab in Moderate-to-Severe Asthma Participants

NCT03387852
completedphase_3

Study of Dupilumab (REGN668/SAR231893) Monotherapy Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis

NCT02277769
completedphase_3

Study of Dupilumab Monotherapy Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis

NCT02277743
completedphase_3

Study to Assess the Efficacy and Long-term Safety of Dupilumab (REGN668/SAR231893) in Adult Participants With Moderate-to-Severe Atopic Dermatitis

NCT02260986
completedphase_2

Study to Assess the Safety of Dupilumab (REGN668/SAR231893) Administered Concomitantly With Topical Corticosteroids (TCS) in Patients With Moderate-to-severe Atopic Dermatitis (AD)

NCT01639040
View all 7 trials

Clinical Trials (7)

Showing 7 of 7 trials
NCT03387852Phase 2

Evaluation of SAR440340 and as Combination Therapy With Dupilumab in Moderate-to-Severe Asthma Participants

Completed
NCT02277769Phase 3

Study of Dupilumab (REGN668/SAR231893) Monotherapy Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis

Completed
NCT02277743Phase 3

Study of Dupilumab Monotherapy Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis

Completed
NCT02260986Phase 3

Study to Assess the Efficacy and Long-term Safety of Dupilumab (REGN668/SAR231893) in Adult Participants With Moderate-to-Severe Atopic Dermatitis

Completed
NCT01639040Phase 2

Study to Assess the Safety of Dupilumab (REGN668/SAR231893) Administered Concomitantly With Topical Corticosteroids (TCS) in Patients With Moderate-to-severe Atopic Dermatitis (AD)

Completed
NCT01920893Phase 2

An Evaluation of Dupilumab in Patients With Nasal Polyposis And Chronic Symptoms Of Sinusitis

Completed
NCT01312961Phase 2

Efficacy, Safety, and Tolerability of Dupilumab in Patients With Persistent Moderate to Severe Eosinophilic Asthma

Completed

All 7 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
7